{"id":"W4324137050","doi":"10.1200/jco.2023.41.6_suppl.166","title":"Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Internal medicine; Cohort; Clinical endpoint; Docetaxel; Androgen receptor; Oncology; Cancer; Androgen deprivation therapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002151107,0.0003682909,0.0008267401,0.0004538251,0.000241277,0.001057331,0.0004789068,0.0005750717,0.001420592],"category_scores_gemma":[0.003309093,0.0002522998,0.002224235,0.0005594485,0.0003385063,0.0008339965,0.0004504081,0.0009938021,0.0002152357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008110107,"about_ca_system_score_gemma":0.0007731321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001381103,"about_ca_topic_score_gemma":0.003212102,"domain_scores_codex":[0.9989043,0.0005216692,0.0001358811,0.0002112483,0.0001108592,0.0001160292],"domain_scores_gemma":[0.9975013,0.0006554353,0.00107578,0.0001535402,0.00009806287,0.0005157593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4710535,0.004958047,0.4476086,0.001102803,0.00638824,0.0001399212,0.0003946804,0.001707538,0.001760544,0.0002162106,0.002675793,0.06199413],"study_design_scores_gemma":[0.0961227,0.178037,0.6987832,0.0005518956,0.01224323,0.0007080713,0.0006922315,0.004794218,0.001582866,0.0005404372,0.005814924,0.0001292445],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954053,0.002770424,0.00006665979,0.0001121639,0.00003201319,0.00009458233,0.0009068826,0.000006108554,0.0006059328],"genre_scores_gemma":[0.9973873,0.0008033905,0.00009736975,0.0002180593,0.0000497799,0.00007321368,0.001146942,0.000003078618,0.0002208093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002151107,"threshold_uncertainty_score":0.01137626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08534680067596,"score_gpt":0.4606475781123941,"score_spread":0.3753007774364341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}